You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DC-CIK

Showing 1 - 25 of 522
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor Trial in Petaling Jaya (Dendritic cell + Cytokine-induced killer cell

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Advanced Solid Tumor
  • Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy
  • Tegafur Only Product
  • Petaling Jaya, Kuala Lumpur, Malaysia
    Clinical Oncology Department, Ummc
Jul 12, 2023

Solid Tumor Trial in Yantai (DC-CIK combined with Chemotherapy, Chemotherapy)

Recruiting
  • Solid Tumor
  • Yantai, Shandong, China
    Yantai Yuhuangding Hospital
Feb 7, 2022

Advanced Liver Cancers Trial (DC-CIK)

Not yet recruiting
  • Advanced Liver Cancers
  • DC-CIK
  • (no location specified)
Nov 11, 2022

Advanced Solid Tumor Trial in Taoyuan (Neoantigen-expanded cell therapy.)

Recruiting
  • Advanced Solid Tumor
  • Neoantigen-expanded cell therapy.
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou
Aug 18, 2021

Liver Cancer, Kidney Cancer, Nasopharyngeal Cancer Trial in Guangzhou (CELL)

Recruiting
  • Liver Cancer
  • +5 more
  • CELL
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 14, 2020

Malignant Tumor Trial in Shenzhen (Decitabine, DC-CIK)

Unknown status
  • Malignant Neoplasm
  • Shenzhen, China
    Shenzhen university general hospital
Feb 28, 2020

Esophageal Carcinoma Trial in Beijing (concurrent chemoradiotherapy plus DC-CIK immunotherapy, Concurrent chemoradiation only)

Unknown status
  • Esophageal Carcinoma
  • concurrent chemoradiotherapy plus DC-CIK immunotherapy
  • Concurrent chemoradiation only
  • Beijing, Beijing, China
    Capital Medical University Cancer Center
Jan 2, 2020

Malignant Tumor Trial in Beijing (DC-CIK Immunotherapy)

Unknown status
  • Malignant Tumor
  • DC-CIK Immunotherapy
  • Beijing, China
    Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospi
Jan 2, 2020

Tumors Trial in Beijing (Anti-PD-1 plus DC-CIK, Anti-PD-1 alone)

Unknown status
  • Neoplasms
  • Anti-PD-1 plus DC-CIK
  • Anti-PD-1 alone
  • Beijing, Beijing, China
    Capital Medical University Cancer Center/Beijing Shijitan Hospit
Oct 31, 2019

Lung Cancer Trial in Guangzhou (DC-CIK, ?d T Cell, ?d T/DC-CIK cells)

Completed
  • Lung Cancer
  • DC-CIK
  • +2 more
  • Guangzhou, Guangdong, China
    Biological treatment center in Fuda cancer hospital
Sep 10, 2019

Lung Cancer, Tumors Trial in Beijing (Anti-PD-1 plus DC-CIK, Anti-PD-1 alone)

Unknown status
  • Lung Cancer
  • Neoplasms
  • Anti-PD-1 plus DC-CIK
  • Anti-PD-1 alone
  • Beijing, China
    Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospi
Nov 3, 2019

Solid Tumor Trial (pd-1 and dc-cik cells)

Unknown status
  • Solid Tumor
  • pd-1 and dc-cik cells
  • (no location specified)
Jan 28, 2019

Hepatocellular Carcinoma Trial in Beijing (adoptive immunotherapy, MWA)

Completed
  • Hepatocellular Carcinoma
  • adoptive immunotherapy
  • MWA
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Mar 2, 2021

Gastric Cancer Trial in Beijing (DC-CIK, S-1, Cisplatin)

Completed
  • Gastric Cancer
  • DC-CIK
  • +2 more
  • Beijing, Beijing, China
    Capital Medical University Cancer Center
Jul 18, 2018

Colorectal Cancer Trial in Chongqing (CIK combined with chemo group, CIK combined immunotherapy group, CIK combined targeted

Recruiting
  • Colorectal Cancer
  • CIK combined with chemotherapy group
  • +3 more
  • Chongqing, Chongqing, China
    Southwest Hospital, Army Medical University (Third Military Medi
Jan 6, 2023

Healthy Volunteers Trial in Groningen (DC-806, [14C]-DC-806)

Recruiting
  • Healthy Volunteers
  • Groningen, Netherlands
    ICON Phase 1 Clinic
Sep 13, 2023

Postoperative Prevention of Tumor Trial in Shanghai (Oral NMN combined with DC cell vaccine)

Not yet recruiting
  • Postoperative Prevention of Tumor
  • Oral NMN combined with DC cell vaccine
  • Shanghai, Shanghai, China
    Shanghai Mengchao Cancer Hospital
Sep 6, 2023

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Dupuytren's Contracture Trial

Not yet recruiting
  • Dupuytren's Contracture
    • (no location specified)
    May 17, 2023

    Plaque Psoriasis Trial in Worldwide (DC-806, Placebo)

    Recruiting
    • Plaque Psoriasis
    • Rogers, Arkansas
    • +62 more
    May 31, 2023

    Sarcoma Trial in Turin (Autologous CIK)

    Recruiting
    • Sarcoma
    • Autologous CIK
    • Turin, Italy
      AOU Città della Salute e della Scienza di Torino - Presidio Infa
    Aug 11, 2022

    Advanced Malignant Solid Tumors Trial in Nanchang (Neoantigen peptide vaccine, Neoantigen-based DC immune preparation)

    Not yet recruiting
    • Advanced Malignant Solid Tumors
    • Neoantigen peptide vaccine
    • Neoantigen-based DC immune preparation
    • Nanchang, Jiangxi, China
      First Affiliated Hospital of Nanchang University
    Mar 1, 2023

    Multiple Myeloma Trial in Boston (Nivolumab, DC/myeloma fusions/GM-CSF)

    Terminated
    Has Results
    • Multiple Myeloma
    • Boston, Massachusetts
      Beth Israel Deaconess Medical Center
    Sep 28, 2022

    Heart Failure, Mitral Valve Insufficiency Trial (Digital consult)

    Recruiting
    • Heart Failure
    • Mitral Valve Insufficiency
    • Digital consult
    • Amsterdam, Noord Holland, Netherlands
    • +4 more
    Jan 26, 2023